Investigational Drug Information for AG-881
✉ Email this page to a colleague
What is the drug development status for AG-881?
AG-881 is an investigational drug.
There have been 10 clinical trials for AG-881.
The most recent clinical trial was a Phase 1 trial, which was initiated on January 5th 2020.
The most common disease conditions in clinical trials are Glioma, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are Agios Pharmaceuticals, Inc., Institut de Recherches Internationales Servier, and Merck Sharp & Dohme LLC.
There are seven US patents protecting this investigational drug and one hundred and eleven international patents.
Summary for AG-881
| US Patents | 7 |
| International Patents | 111 |
| US Patent Applications | 28 |
| WIPO Patent Applications | 6 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2020-01-05) |
| Vendors | 39 |
Recent Clinical Trials for AG-881
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function | Institut de Recherches Internationales Servier | Phase 1 |
| Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive Enhancing IDH-1 Mutant Astrocytomas | Merck Sharp & Dohme LLC | Phase 1 |
| Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive Enhancing IDH-1 Mutant Astrocytomas | Institut de Recherches Internationales Servier | Phase 1 |
Clinical Trial Summary for AG-881
Top disease conditions for AG-881
Top clinical trial sponsors for AG-881
US Patents for AG-881
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AG-881 | ⤷ Sign Up | Therapeutically active compounds and their methods of use | Agios Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Sign Up |
| AG-881 | ⤷ Sign Up | Therapeutically active compounds and their methods of use | Agios Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Sign Up |
| AG-881 | ⤷ Sign Up | Methods of treating brain tumors using combination therapy | Agios Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Sign Up |
| AG-881 | ⤷ Sign Up | ⤷ Sign Up | ||
| AG-881 | ⤷ Sign Up | ⤷ Sign Up | ||
| AG-881 | ⤷ Sign Up | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC (Cambridge, MA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AG-881
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AG-881 | Argentina | AR096902 | 2033-07-11 | ⤷ Sign Up |
| AG-881 | Australia | AU2014289744 | 2033-07-11 | ⤷ Sign Up |
| AG-881 | Australia | AU2019201179 | 2033-07-11 | ⤷ Sign Up |
| AG-881 | Brazil | BR112016000561 | 2033-07-11 | ⤷ Sign Up |
| AG-881 | Brazil | BR122017014843 | 2033-07-11 | ⤷ Sign Up |
| AG-881 | Canada | CA2917358 | 2033-07-11 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
